Structure-property relationships in manganese oxide - nnesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery
Structure-property relationships in manganese oxide - nnesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery
复制标题
DOI：
10.1016/j.biomaterials.2011.11.086
复制
发表时间：
2012-03-01
期刊：
影响因子：
14
通讯作者：
Shi, Jianlin
中科院分区：
文献类型：
--
作者：
Chen, Yu;Chen, Hangrong;Shi, Jianlin
氧化锰的极低纵向松弛度（R（1））严重阻碍了它们代替基于细胞毒性的基于细胞毒性的造影剂，用于安全的临床磁共振成像（MRI）。在这里，我们报告了中孔中的化学氧化/还原反应的合成策略，其次是氢还原，用于制造非毒性氧化锰/MSNS的MRI-T-1对比剂，具有与基于GD的GD代理高度可比的成像性能。该策略涉及制备中孔二氧化硅纳米颗粒的“软”过程，通过中孔中的“软模板”对Mno4-的原位减少，并在还原气氛下进行热处理，以分散中孔内的锰氧化物纳米颗粒。这种特殊的纳米结构结合了纳米孔的优点，用于水分子的最大锰顺磁中心可及性，以增强MRI性能和封装/持续释放/细胞内递送药物。成功评估了合成的氧化锰/MSN作为在介绍和体内MRI-T-1的高性能对比剂评估，同时也被证明是一种有效的抗癌药物（阿霉素），基于锰基剂的家族，基于基于锰的TheraneStics家族，基于基于锰的TheraneStics家族。 （c）2011 Elsevier Ltd.保留所有权利。
The extremely low longitudinal relaxivity (r(1)) of manganese oxide has severely impeded their substitution for cytotoxic gadolinium-based contrast agents for safe clinical magnetic resonance imaging (MRI). Here, we report on a synthetic strategy of chemical oxidation/reduction reaction in-situ in mesopores, followed by hydrogen reduction, for the fabrication of non-toxic manganese oxide/MSNs-based MRI-T-1 contrast agents with highly comparable imaging performance to commercial Gd-based agents. This strategy involves a "soft-templating" process to prepare mesoporous silica nanoparticles, in-situ reduction of MnO4- by the "soft templates" in mesopores and heat treatment under reducing atmosphere, to disperse manganese oxide nanoparticles within mesopores. This special nanostructure combines the merits of nanopores for maximum manganese paramagnetic center accessibility for water molecules for enhanced MRI performance and encapsulation/sustained release/intracellular delivery of drugs. The synthesized manganese oxide/MSNs were successfully assessed as a high performance contrast agent for MRI-T-1 both in intro and in vivo, and meanwhile, was also demonstrated as an effective anti-cancer drug delivery (doxorubicin) vehicle, therefore, a family of manganese-based theranostics was successfully demonstrated based on the manganese oxide/MSNs composite. (C) 2011 Elsevier Ltd. All rights reserved.